What is the 13F Pro Quality Score for IMCR?

13F Pro ranks Immunocore Holdings plc (IMCR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IMCR's current score at https://13fpro.ai/research/IMCR (free sign-up required for the full ranking).

Which hedge funds own the most IMCR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IMCR include RTW INVESTMENTS,, FMR, WELLINGTON MANAGEMENT GROUP LLP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/IMCR as soon as new 13F filings post.

Where does 13F Pro source IMCR data?

All Immunocore Holdings plc fundamentals and ownership data come directly from SEC EDGAR. Immunocore Holdings plc files with the SEC under CIK 1671927. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IMCR in?

Immunocore Holdings plc (IMCR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IMCR research updated on 13F Pro?

IMCR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Immunocore Holdings plc(IMCR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1671927 IMCR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

IMCR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Immunocore Holdings plc (IMCR), a Healthcare sector company. IMCR is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Immunocore Holdings plc reports quarterly revenue of $106.7M, net income of $13.0M, free cash flow of $-15.6M. Top institutional holders of IMCR by reported 13-F value include RTW INVESTMENTS,, FMR, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. IMCR trades on the Nasdaq exchange and files with the SEC under CIK 1671927. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immunocore Holdings plc directly from SEC EDGAR.

Revenue

Q1 2026

$106.7M

Net Income

Q1 2026

$13.0M

Free Cash Flow

Q1 2026

$-15.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+60.4% YoY

$400.0MFY 2025

FY20 $30.1MFY23 $249.4MFY25 $400.0M

Net Income

+35.8% YoY

$-35.5MFY 2025

FY20 —FY23 $-55.3MFY25 $-35.5M

Operating Income

+24.0% YoY

$-45.4MFY 2025

FY20 —FY23 $-59.6MFY25 $-45.4M

EPS (Diluted)

+37.2% YoY

$-0.71FY 2025

FY20 —FY23 $-1.13FY25 $-0.71

Total Assets

+78.8% YoY

$1.07BFY 2025

FY20 $197.2MFY23 $597.0MFY25 $1.07B

Op. Cash Flow

-464.4% YoY

$-10.7MFY 2025

FY20 —FY23 $2.9MFY25 $-10.7M

Metric	FY 2025	FY 2023	FY 2020
Revenue	$400.0M +60.4%	$249.4M +728.3%	$30.1M
Net Income	$-35.5M +35.8%	$-55.3M	—
Operating Income	$-45.4M +24.0%	$-59.6M	—
EPS (Diluted)	$-0.71 +37.2%	$-1.13	—
Total Assets	$1.07B +78.8%	$597.0M +202.7%	$197.2M
Operating Cash Flow	$-10.7M -464.4%	$2.9M	—

AI Insight: IMCR Financial Trends

Immunocore reached its first positive operating income in the observed period in Q1 2026 at $7M, even as operating cash flow remained deeply negative at -$14M.

• Revenue grew steadily from $75M in Q2 2024 to $107M in Q1 2026, a 43% increase over seven quarters.

• Operating income turned positive for the first time in Q1 2026 at $7M, versus -$20M in Q4 2025.

• Operating cash flow is highly volatile, swinging from +$26M in Q2 2025 to -$33M in Q4 2025 and -$14M in Q1 2026.

• Equity edged up from $359M in Q2 2024 to $394M in Q1 2026, showing modest balance-sheet stability.

⚠ Operating cash flow has been negative in three of the last four quarters; conversion of revenue growth into cash remains elusive.

⚠ Debt data is absent from Q4 2024 onward — inability to track leverage trajectory is a key information gap.

⚠ Net income remains erratic, ranging from -$30M in Q4 2025 to +$13M in Q1 2026; sustainable profitability is unconfirmed.

AI Insight: IMCR Ratio Trends

Q1 2026 marks Immunocore's first profitable quarter on record, with operating margin flipping to +6.8% and ROIC turning positive at +7.4%.

• Operating margin swung from -18.9% in Q4 2025 to +6.8% in Q1 2026 — first positive reading in the dataset.

• ROIC turned positive at +7.4% in Q1 2026, reversing six consecutive quarters of negative returns on invested capital.

• TTM operating margin remains negative at -8.3%, reflecting heavy losses in Q4 2024 and Q4 2025 dragging the full-year figure.

⚠ Q4 quarters have been deeply loss-making (-23.1% in Q4 2024, -18.9% in Q4 2025); watch whether Q4 2026 repeats this seasonal pattern.

⚠ D/E data is absent from Q4 2024 onward; leverage visibility is limited and warrants monitoring as losses accumulate.

⚠ Q1 2026 profitability may reflect a one-time revenue event; TTM margin of -8.3% signals underlying business is not yet sustainably profitable.

Get alerted when IMCR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Immunocore Holdings plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IMCR

RTW INVESTMENTS, LP
$146.8M4,869,798 sh
FMR LLC
$145.6M4,829,154 sh
WELLINGTON MANAGEMENT GROUP LLP
$141.9M4,706,168 sh
PRIMECAP MANAGEMENT CO/CA/
$111.4M3,693,241 sh
Bellevue Group AG
$84.3M2,796,803 sh
Vestal Point Capital, LP
$83.4M2,766,868 sh
LINDEN ADVISORS LP
$81.9M90,836,000 sh
TANG CAPITAL MANAGEMENT LLC
$79.9M2,649,368 sh
Context Capital Management, LLC
$70.2M77,841,000 sh
Deep Track Capital, LP
$58.2M1,931,884 sh

Fund	Value	Shares
RTW INVESTMENTS, LP	$146.8M	4,869,798
FMR LLC	$145.6M	4,829,154
WELLINGTON MANAGEMENT GROUP LLP	$141.9M	4,706,168
PRIMECAP MANAGEMENT CO/CA/	$111.4M	3,693,241
Bellevue Group AG	$84.3M	2,796,803
Vestal Point Capital, LP	$83.4M	2,766,868
LINDEN ADVISORS LP	$81.9M	90,836,000
TANG CAPITAL MANAGEMENT LLC	$79.9M	2,649,368
Context Capital Management, LLC	$70.2M	77,841,000
Deep Track Capital, LP	$58.2M	1,931,884

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IMCR on your watchlist

Track score changes the day Immunocore Holdings plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IMCR a good stock to buy?

13F Pro's AI-powered analysis of Immunocore Holdings plc (IMCR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMCR are available on the IMCR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IMCR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMCR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Immunocore Holdings plc's investment landscape.